[Prospects for differentiated conservative treatment of patients with benign prostatic hyperplasia].
The results of conservative therapy of 30 patients aged from 50 to 79 years with benign hyperplasia of prostate according to the IPSS scale from 7 to 30 points were analyzed. Under the influence of treatment in all the patients the clinical symptoms severity, according to the monitoring data using the IPSS tables, had reduced by 72% at average and quality of life improve no less than by 50%. Average efficacy of the volume and volumetric of urination had enhanced according to uroflowmetry data.
Danilov
V V
VV
Borshchenko
S A
SA
Danilova
T I
TI
Medvedeva
I A
IA
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D000975:Antioxidants / Q000627:therapeutic use; D004338:Drug Combinations; D006801:Humans; D006965:Hyperplasia / Q000473:pathology; D008297:Male; D008875:Middle Aged; D008903:Minerals / Q000627:therapeutic use; D011467:Prostate / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011788:Quality of Life; D016896:Treatment Outcome; D014815:Vitamins / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000975:Antioxidants; D004338:Drug Combinations; C050178:Komplivit; D008903:Minerals; D014815:Vitamins; C044905:nicotinoyl-GABA; D005680:gamma-Aminobutyric Acid